Well-Established Use (WEU) is a term commonly used in the field of pharmaceuticals and medicine to describe a specific category of drug approvals. When a medication is classified as “well-established use,” the drug has been in extensive medical use for a considerable period, typically several years or more. During this time, the medication has demonstrated a solid track record of safety and efficacy, supported by a substantial body of clinical data and real-world evidence.
The concept of well-established use is particularly relevant when it comes to regulatory approvals for pharmaceuticals. In many countries, drug regulatory agencies have established different pathways for the approval of new medications. For novel drugs, extensive clinical trials and preclinical studies are required to establish their safety and effectiveness. However, for drugs that have been used for a long time and have accumulated a wealth of clinical experience, a more streamlined approval process might be available, which considers the wealth of historical data and clinical evidence.
The designation of well-established use acknowledges that the drug has already been proven safe and effective in the treatment of specific medical conditions, and as a result, the regulatory process for its approval may be expedited. This can be particularly beneficial when a patient’s health condition necessitates immediate access to a well-known and reliable treatment option.
It is important to note that the concept of well-established use should not be confused with off-label use. Well-established use implies that the drug’s use for specific indications is widely recognized and supported by scientific evidence and regulatory bodies. In contrast, off-label use refers to the use of a medication in a manner not explicitly approved by regulatory authorities or described in the official prescribing information.
Confounding by Indication
Contact our experts today
Composed of proven experts from the pharmaceutical industry, our team is ready to answer to your needs in any
area of product development, commercialisation and early access programs, and life cycle management